-
公开(公告)号：US10010549B2
公开(公告)日：2018-07-03
申请号：US14927267
申请日：2015-10-29
Applicant: Genentech, Inc.
Inventor： Anthony Estrada , Liting Dong , Kevin X. Chen , Paul Gibbons , Malcolm Huestis , Terry Kellar , Wen Liu , Changyou Ma , Joseph Lyssikatos , Alan Olivero , Snahel Patel , Daniel Shore , Michael Siu
IPC: A61K31/506 , A61K31/4545 , A61K31/5377 , A61K31/55 , A61K35/30 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/18 , C07D487/08 , C07D491/08 , C07D495/08 , C07D519/00 , C07D471/08 , A61K45/06 , A61K31/5386 , A61K31/553 , C07D417/14 , C07D487/14 , C07D487/18 , A61K31/444
CPC classification number: A61K31/506 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/5386 , A61K31/55 , A61K31/553 , A61K35/30 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D471/18 , C07D487/08 , C07D487/14 , C07D487/18 , C07D491/08 , C07D495/08 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
-
公开(公告)号：US11247989B2
公开(公告)日：2022-02-15
申请号：US16198581
申请日：2018-11-21
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Patrick Cyr , Sarah Bronner , F. Anthony Romero , Steven Magnuson , Vickie Hsiao-Wei Tsui , Jeremy M. Murray , John Wai , Kwong Wah Lai , Fei Wang , Kevin X. Chen
IPC: C07D471/04 , C07D519/00
Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US11129832B2
公开(公告)日：2021-09-28
申请号：US16666273
申请日：2019-10-28
Applicant: Genentech, Inc.
Inventor： Anthony Estrada , Liting Dong , Kevin X. Chen , Paul Gibbons , Malcolm Huestis , Terry Kellar , Wen Liu , Changyou Ma , Joseph P. Lyssikatos , Alan G. Olivero , Snahel Patel , Daniel Shore , Michael Siu
IPC: C07D471/08 , A61K31/506 , A61K45/06 , A61K31/5386 , A61K31/4545 , A61K31/5377 , A61K31/55 , A61K35/30 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/18 , C07D487/08 , C07D491/08 , C07D495/08 , C07D519/00 , A61K31/553 , C07D417/14 , C07D487/14 , C07D487/18 , A61K31/444
Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
-
公开(公告)号：US20180133219A1
公开(公告)日：2018-05-17
申请号：US15868301
申请日：2018-01-11
Applicant: Genentech, Inc.
Inventor： Anthony Estrada , Liting Dong , Kevin X. Chen , Paul Gibbons , Malcolm Huestis , Terry Kellar , Wen Liu , Changyou Ma , Joseph Lyssikatos , Alan Olivero , Snahel Patel , Daniel Shore , Michael Siu
IPC: A61K31/506 , A61K31/444 , A61K35/30 , C07D487/14 , A61K31/553 , C07D417/14 , C07D487/18 , A61K31/55 , C07D401/14 , A61K31/5377 , C07D495/08 , A61K31/4545 , C07D519/00 , A61K31/5386 , A61K45/06 , C07D471/08 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D471/18 , C07D487/08 , C07D491/08
CPC classification number: A61K31/506 , A61K31/444 , A61K31/4545 , A61K31/5377 , A61K31/5386 , A61K31/55 , A61K31/553 , A61K35/30 , A61K45/06 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/08 , C07D471/18 , C07D487/08 , C07D487/14 , C07D487/18 , C07D491/08 , C07D495/08 , C07D519/00 , A61K2300/00
Abstract: The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R1, R2, R3, X1, X2, A and Cy variable in Formula I-I all have the meaning as defined herein.
-
Patent Agency Ranking
公开(公告)号：US20170333406A1
公开(公告)日：2017-11-23
申请号：US15667227
申请日：2017-08-02
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Marc Adler , Brian K. Albrecht , Sarah Bronner , Kevin X. Chen , Alexandre Côté , Terry Crawford , Patrick Cyr , Jackson Egen , Steven Kauder , Kwong Wah Lai , Jiangpeng Liao , Steven Magnuson , Jeremy Murray , Richard Pastor , F. Anthony Romero , Alexander M. Taylor , Vickie Hsiao-Wei Tsui , Fei Wang , Bing-Yan Zhu
IPC: A61K31/437 , C07D471/04 , A61K45/06 , A61K31/55 , A61K31/5415 , A61K31/5377 , A61K31/4375 , A61K31/506 , A61K31/498 , A61K31/496 , A61K31/4725 , A61K31/4709 , C07D519/00 , A61K31/538
CPC classification number: A61K31/437 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5415 , A61K31/55 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US20160158207A1
公开(公告)日：2016-06-09
申请号：US14952821
申请日：2015-11-25
Applicant: Constellation Pharmaceuticals, Inc. , Genentech, Inc.
Inventor： Marc Adler , Brian K. Albrecht , Sarah Bronner , Kevin X. Chen , Alexandre Côté , Terry Crawford , Patrick Cyr , Jackson Egen , Steven Kauder , Kwong Wah Lai , Jiangpeng Liao , Steven Magnuson , Jeremy Murray , Richard Pastor , F. Anthony Romero , Alexander M. Taylor , Vickie Hsiao-Wei Tsui , Fei Wang , Bing-Yan Zhu
IPC: A61K31/437 , A61K31/538 , A61K31/5415 , A61K31/4709 , A61K31/498 , A61K45/06 , A61K31/55 , C07D519/00 , A61K31/4375 , A61K31/4725 , A61K31/496 , A61K31/5377 , C07D471/04 , A61K31/506
CPC classification number: A61K31/437 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5415 , A61K31/55 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
Abstract translation: 本发明涉及式（I）或式（II）化合物及其盐，其中式（I）的R 1 -R 4和式（II）的R 1 -R 3具有本文定义的任何值，组合物 及其用途。 该化合物可用作CBP和/或EP300的抑制剂。 还包括包含式（II）的式（I）化合物或其药学上可接受的盐的药物组合物，以及在治疗各种CBP和/或EP300介导的病症中使用这些化合物和盐的方法。
-
公开(公告)号：US20220127265A1
公开(公告)日：2022-04-28
申请号：US17570139
申请日：2022-01-06
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Patrick Cyr , Sarah Bronner , F. Anthony Romero , Steven Magnuson , Vickie Hsiao-Wei Tsui , Jeremy M. Murray , John Wai , Kwong Wah Lai , Fei Wang , Kevin X. Chen
IPC: C07D471/04 , C07D519/00
Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US20190241558A1
公开(公告)日：2019-08-08
申请号：US16198581
申请日：2018-11-21
Applicant: GENENTECH, INC. , CONSTELLATION PHARMACEUTICALS, INC.
Inventor： Patrick Cyr , Sarah Bronner , F. Anthony Romero , Steven Magnuson , Vickie Hsiao-Wei Tsui , Jeremy M. Murray , John Wai , Kwong Wah Lai , Fei Wang , Kevin X. Chen
IPC: C07D471/04
CPC classification number: C07D471/04 , C07D519/00
Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
公开(公告)号：US09763922B2
公开(公告)日：2017-09-19
申请号：US14952821
申请日：2015-11-25
Applicant: Genentech, Inc. , Constellation Pharmaceuticals, Inc.
Inventor： Marc Adler , Brian K. Albrecht , Sarah Bronner , Kevin X. Chen , Alexandre Côté , Terry Crawford , Patrick Cyr , Jackson Egen , Steven Kauder , Kwong Wah Lai , Jiangpeng Liao , Steven Magnuson , Jeremy Murray , Richard Pastor , F. Anthony Romero , Alexander M. Taylor , Vickie Hsiao-Wei Tsui , Fei Wang , Bing-Yan Zhu
IPC: A61K31/437 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5415 , A61K31/55 , C07D471/04 , C07D519/00 , A61K45/06
CPC classification number: A61K31/437 , A61K31/4375 , A61K31/4709 , A61K31/4725 , A61K31/496 , A61K31/498 , A61K31/506 , A61K31/5377 , A61K31/538 , A61K31/5415 , A61K31/55 , A61K45/06 , C07D471/04 , C07D519/00
Abstract: The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
-
-
-
-
-
-
-
-
Search Results
9
records
(took 0.05 seconds)
